

Recent News

First Site for Phase 2 “ASSURE 1” Trial Activated

The first site for the ASSURE 1 trial, led by Cleveland Clinic is activated and enrollment of patients has commenced. This IVUS study is comprised of 15–20 US sites will dose approximately 120 ACS patients on standard of care therapy and examine lipid effects by RVX-208 compared to placebo control. In half of the patients a change in atherosclerosis will be assessed, i.e. change in plaque volume and plaque composition. The primary objective of this study is to determine the 3 month effect of RVX-208 on change in the plasma levels of ApoA-I in patients with a recent ACS event who require coronary angiography versus placebo. The secondary objectives for this study include assessing the safety and tolerability of the drug through evaluation of adverse events as well as to evaluate the effect of RVX-208 on other lipid parameters. Resverlogix anticipates it will be able to describe early trends for the relationship between RVX-208 and changes in lipid parameters, changes in measures of atheroma burden and plaque composition. Destum Partner’s research concluded that by using an ApoA-I increasing therapy in patients as a secondary prevention measure, outcomes could be significantly improved and the potential savings to the US health care system, society and employers beyond current standard of care are from US \$22.9 billion and US \$76.8 billion annually, for a 1% to 5% regression of atherosclerosis, respectively.

Recruitment for Phase 2 “ASSERT” Trial Completed

Patient enrollment in the ASSERT Phase 2 clinical trial at Cleveland Clinic study has been completed a full 5 months ahead of the original schedule. At this rate we could be seeing the final dosed patient in May of 2010. Once completed, the randomized, double-blind, placebo-controlled, multi-centered US study will have administered RVX-208 to approximately 280 patients with stable coronary artery disease for a period of 13 weeks. The primary objective of this study is to determine if RVX-208 will produce an increase in plasma apolipoprotein A-I (ApoA-I) levels compared to placebo group after three months of dosing. The secondary objectives are to examine the safety and tolerability of RVX-208, to compare the dose and time response relationships for ApoA-I over time as well as to examine key reverse cholesterol markers describing HDL functionality.

Arthur Higgins Joins RVX Board of Directors

On February 1, 2010 Resverlogix announced that the Board of Directors elected Arthur J. Higgins, CEO of Bayer HealthCare and Chairman of the Bayer HealthCare Executive Committee, to the Board effective February 1, 2010. Mr. Higgins joined Bayer in 2004 as Chairman of the Bayer HealthCare Executive Committee and in 2006 was named Chairman of the Board of Management of Bayer HealthCare. Mr. Higgins has played a key role in driving the success of Bayer HealthCare through a combination of strong organic growth and key acquisitions, including the €17 billion acquisition of the German pharmaceutical company, Schering AG, in 2006.

Second Tranche Financing Totals \$13 Million

January 28, 2010 it was announced by Resverlogix that it had completed a CDN \$8 million second tranche of its equity private placement announced on December 23, 2009. Under the terms and conditions of the private placement, Resverlogix issued units (the “Units”) at a price of \$2.50 per Unit, with each Unit comprising of one common share (a “Common Share”) and one quarter of a warrant. This second tranche, together with the first tranche that closed on December 18, 2009, brings the total proceeds of the financing to CDN \$13 million.

Resverlogix Eliminates Debt

Resverlogix announced on January 7, 2010 that it has completed the previously announced redemption of the outstanding convertible notes 2.5 years prior to maturity. A total of US \$6.728 million of convertible debt, due June 6, 2012, has been redeemed.

Upcoming Conferences

Bio Europe Spring March 8-10, Barcelona, Spain.

American College of Cardiology Annual Scientific Meetings, March 14-16, Atlanta, GA.

Arteriosclerosis, Thrombosis and Vascular Biology 2010 Scientific Sessions, April 8–10, San Francisco, CA.

Rodman & Renshaw Global Investment conference May 15-19, London, England.

BIO Equity Europe, May 19-20, 2010, Zurich, Switzerland.

IAS HDL Forum, May 17-21, Whistler, B.C.

Market Opportunity


CVD is the leading killer of men and women in the industrialized world with over 18 million deaths reported in 2005 (WHO). One person will die every 30 seconds from CVD in the United States alone. The American Heart Association estimates that in 2007 roughly 80 million adults in the United States have one or more types of CVD. Drugs for the treatment of cardiovascular disease represent the largest pharmaceutical market opportunity in the world at US \$30-50 billion annually. There exists a huge unmet medical need for new cardiovascular therapies. Future estimates indicate that CVD mortality will increase by 90% by the year 2020 versus rates in 1990. The American Heart Association estimates the direct and indirect costs of CVD in the United States alone for 2007 are US \$431.8 billion.

About Resverlogix

Resverlogix Corp. (Toronto Stock Exchange: RVX) is a Canadian biotechnology company with a world lead in developing a new class of drugs for cardiovascular disease (CVD). **NexVas™ Plaque Regression (NexVas PR)**, is a novel technology platform with drugs that increase apolipoprotein A-I (ApoA-I) to reduce atherosclerosis (fatty plaque build-up in the arteries), which is the leading cause of CVD. ApoA-I is the key protective protein of high density lipoprotein (HDL), commonly known as the “good cholesterol”. Current drugs on the market only manage atherosclerosis burden but they have very limited or no effect on atherosclerosis regression. NexVas PR aims to manage and regress atherosclerosis. Resverlogix’s lead ApoA-I drug **RVX-208** completed a Phase 1b/2a human clinical trial. The Phase 2 ASSERT and ASSURE 1 trials led by Cleveland Clinic have commenced. The NexVas PR proprietary small molecule library also has potential in other therapeutic areas, including inflammatory diseases and Alzheimer’s disease.

Resverlogix Corp. trades on the Toronto Stock Exchange under the symbol ‘RVX’

www.resverlogix.com



HDL Molecule

© Resverlogix Corp.




Fact Sheet March 2010

About Atherosclerosis and ApoA-I

According to the World Health Organization, one person will die every 30 seconds from cardiovascular disease (CVD) in the United States alone. Atherosclerosis results from the build-up of fat and cholesterol in the artery wall, leading to a plaque that causes narrowing and hardening of the arteries, resulting in a loss of elasticity and function. Atherosclerosis is the underlying cause of CVD. ApoA-I is the key protein in high-density lipoprotein (HDL) also known as the “good cholesterol”. The beneficial role of ApoA-I continues to be established by demonstrating both the ability of reverse cholesterol transport (RCT) of arterial plaque and reduction of CVD risk. Thereby ApoA-I has secured the moniker, “the cardio-protective protein.” There is now a major paradigm shift in research and development of novel therapeutics that focus on ApoA-I production for the future management of CVD and atherosclerosis.

Resverlogix continues to build upon its world lead in this novel area of drug development. Current drugs on the market only manage atherosclerosis burden but they have very limited or no effect on atherosclerosis regression. NexVas PR aims to manage and regress atherosclerosis.

ATHEROSCLEROSIS DEVELOPMENT IN AN ARTERY



Investor Contacts:

Theresa Kennedy

VP Corporate Communications

e. theresa@resverlogix.com

ph. 604.538.7072

Sarah Zapotichny

Manager Investor Relations

e. sarah@resverlogix.com

ph. 403.254.9252